Ceritinib 150 mg

Detailed Description — Ceritinib 150 mg

Ceritinib 150 mg is a targeted therapy classified as an ALK (anaplastic lymphoma kinase) inhibitor. It is used primarily for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that test positive for ALK gene rearrangements. Ceritinib works by blocking the abnormal ALK protein, which drives cancer cell proliferation, thereby slowing tumor growth and progression.

Ceritinib is particularly valuable for patients who have either relapsed or are resistant to previous ALK-targeted treatments, such as crizotinib. It is taken orally, allowing patients to receive therapy conveniently at home under medical supervision.

How Ceritinib Works

Ceritinib works by:

• Inhibiting the ALK tyrosine kinase, a protein responsible for abnormal cancer cell signaling

• Preventing cancer cells from dividing and growing

• Inducing apoptosis (programmed cell death) in cancer cells

• Targeting tumors with ALK gene rearrangements while sparing most normal cells

This targeted approach reduces tumor burden and slows disease progression compared to traditional chemotherapy.

Uses of Ceritinib 150 mg

Ceritinib 150 mg is prescribed for:

• ALK-positive advanced NSCLC

• Patients who have relapsed or progressed after other ALK inhibitors

• As a first-line treatment for newly diagnosed ALK-positive NSCLC (based on clinical guidance)

It is not effective for ALK-negative NSCLC or other types of lung cancer.

Dosage & Administration

• Typical dose: 150 mg orally once daily (dose may vary depending on the formulation or combination therapy)

• Swallow tablets whole with water

• Can be taken with or without food, though some formulations may require administration with food

• Take at the same time each day

• Do not crush, chew, or split tablets

Dosage adjustments may be required for liver impairment or severe side effects. Always follow the prescribing oncologist’s instructions.

Benefits of Ceritinib 150 mg

• Targets ALK-positive cancer cells specifically

• Effective in patients resistant to other ALK inhibitors

• Reduces tumor growth and may shrink tumors

• Convenient oral therapy allows home administration

• Can improve progression-free survival and quality of life

Possible Side Effects

Common side effects:

• Nausea and vomiting

• Diarrhea or constipation

• Fatigue

• Elevated liver enzymes

• Loss of appetite

Serious side effects (require immediate attention):

• Liver toxicity

• Severe diarrhea or dehydration

• Interstitial lung disease or pneumonitis

• Heart rhythm disturbances (QT prolongation)

• Severe allergic reactions

Patients should report any unexplained symptoms or severe side effects immediately to their doctor.

Precautions & Warnings

• Monitor liver function and heart rhythm during therapy

• Avoid use in patients with severe liver disease unless directed by a doctor

• Use contraception during treatment and for some time after, as ceritinib may harm a fetus

• Not recommended for use in ALK-negative lung cancer

• Inform your doctor about all current medications, including supplements

Drug Interactions

Ceritinib may interact with:

• CYP3A4 inhibitors or inducers (affecting drug levels)

• Certain anticoagulants, antiarrhythmics, and statins

• Other medications that affect QT interval

It is critical to review all medications with your oncologist before starting treatment.

Storage Instructions

• Store at 20–25°C (room temperature)

• Keep in original packaging, protected from moisture and light

• Do not freeze

• Keep out of reach of children

• Do not use after the expiration date

External Reference

For more detailed information about ceritinib, visit:
🔗 https://www.drugs.com/ceritinib.html

Frequently Asked Questions (FAQ)

1. What is Ceritinib 150 mg used for?
It is used to treat ALK-positive non-small cell lung cancer (NSCLC), especially in patients resistant to prior ALK inhibitors.

2. How does it work?
Ceritinib inhibits the ALK protein, preventing cancer cell growth and inducing cell death.

3. Can it be used for ALK-negative lung cancer?
No, it is effective only in ALK-positive tumors.

4. How long does treatment last?
Duration depends on response and tolerability, typically until disease progression or unacceptable side effects.

5. Are there common side effects?
Yes, including nausea, diarrhea, fatigue, and elevated liver enzymes. Severe side effects are rare but possible.

6. Can it be taken with food?
Some formulations may require food for optimal absorption; follow your doctor’s instructions.

7. Is monitoring required?
Yes, liver function tests, heart rhythm monitoring, and regular imaging are recommended during therapy.